Fate Therapeutics

Historical price data

Fate Therapeutics is dedicated to transforming patient lives with autoimmune diseases and cancer through its proprietary iPSC platform, which generates 'off-the-shelf' cell therapies. The company's mission is to make cell therapy delivery routine and accessible by developing multiplexed-engineered cell product candidates that incorporate novel synthetic controls of cell function. Its pipeline includes several clinical-stage candidates, such as FT819, FT825, FT836, FT839, and FT522, targeting both oncology and autoimmune indications. Fate operates as a public company, leveraging strategic collaborations to advance its science and clinical development.

Proprietary induced pluripotent stem cell (iPSC) platform used to create clonal master cell lines for the scalable, off-the-shelf manufacturing of multiplexed-engineered cell therapies, including CAR T-cells, NK cells, and regulatory T-cells (Tregs).

21 drugs in pipeline

Total raised: $272M

Fate competes with other allogeneic cell therapy companies like Allogene Therapeutics and CRISPR Therapeutics, as well as autologous leaders like Novartis and Gilead. Its key differentiation is the use of a clonal iPSC starting material, which aims to provide superior scalability, consistency, and capacity for complex genetic engineering compared to donor-derived approaches.